adagrasib
mirati
['9002', 'krystal-1', 'mrtx849', 'sclc', 'nsclc', 'adagrasib']
 at #asco2022 oral presentation (abstract #9002)/effect of adagrasib (mrtx849) in patients with nsclc titled, krystal-1: activity and safety of adagrasib (mrtx849) in pts with (nsclc) harboring a krasg12c mutation. friday, june 3 at 1:24 p.m. 
40+yrs. Virginia Cancer Specialists: Prevention. Detection. Diagnosis. Treatment. Radiation. Surgery. Clinical Trial Phase 1+/Oncology Research Space NOVA